HealthWhat Are Vaccines Doing to Our Bodies, and Could Sugars Make the Vaccines Better?
The emerging interest in modulating antibody effector activity against pathogens and developing strategies that can modulate antibody effector function in vivo are highly desirable. A major stumbling block in the design of such vaccines is a lack of technology to determine protein glycosylation sites. A considerable expansion in glycomics capabilities will be required to fully exploit protein glycosylation for the development of new vaccines.
By Tea Petrovic
